Posizolid: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|An overview of the antibiotic Posizolid}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 123456789 | |||
| image = Posizolid.png | |||
| image_size = 250px | |||
| image_alt = Chemical structure of Posizolid | |||
}} | |||
'''Posizolid''' is a synthetic antibiotic belonging to the [[oxazolidinone]] class, which is used to treat infections caused by [[Gram-positive bacteria]]. It is particularly effective against [[methicillin-resistant Staphylococcus aureus]] (MRSA) and [[vancomycin-resistant Enterococcus]] (VRE). | |||
Posizolid | |||
== Mechanism of Action == | ==Mechanism of Action== | ||
Posizolid works by inhibiting bacterial [[protein synthesis]]. It binds to the 50S subunit of the bacterial [[ribosome]], preventing the formation of the 70S initiation complex, which is essential for bacterial translation. This action is bacteriostatic against most organisms but can be bactericidal against certain strains of [[Streptococcus]]. | |||
== | ==Pharmacokinetics== | ||
Posizolid is well absorbed orally, with a bioavailability of approximately 90%. It is widely distributed in body tissues and fluids, including the [[central nervous system]]. The drug is metabolized in the liver and excreted primarily in the urine. | |||
== | ==Clinical Uses== | ||
Posizolid is used to treat a variety of infections, including: | |||
* [[Skin and soft tissue infections]] | |||
* [[Pneumonia]] | |||
* [[Bacteremia]] | |||
It is often reserved for use in cases where other antibiotics are ineffective due to resistance. | |||
== | ==Side Effects== | ||
Common side effects of Posizolid include: | |||
* [[Nausea]] | |||
* [[Diarrhea]] | |||
* [[Headache]] | |||
Serious side effects can include [[myelosuppression]], [[peripheral neuropathy]], and [[lactic acidosis]]. | |||
==Resistance== | |||
Resistance to Posizolid is relatively rare but can occur through mutations in the 23S rRNA of the bacterial ribosome or through the acquisition of the cfr gene, which confers resistance to multiple antibiotic classes. | |||
==Related pages== | |||
* [[Antibiotic resistance]] | |||
* [[Oxazolidinone]] | * [[Oxazolidinone]] | ||
* [[ | * [[Gram-positive bacteria]] | ||
[[Category:Antibiotics]] | [[Category:Antibiotics]] | ||
[[Category:Oxazolidinones]] | [[Category:Oxazolidinones]] | ||
Revision as of 03:41, 13 February 2025
An overview of the antibiotic Posizolid
| Posizolid | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Posizolid is a synthetic antibiotic belonging to the oxazolidinone class, which is used to treat infections caused by Gram-positive bacteria. It is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).
Mechanism of Action
Posizolid works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, preventing the formation of the 70S initiation complex, which is essential for bacterial translation. This action is bacteriostatic against most organisms but can be bactericidal against certain strains of Streptococcus.
Pharmacokinetics
Posizolid is well absorbed orally, with a bioavailability of approximately 90%. It is widely distributed in body tissues and fluids, including the central nervous system. The drug is metabolized in the liver and excreted primarily in the urine.
Clinical Uses
Posizolid is used to treat a variety of infections, including:
It is often reserved for use in cases where other antibiotics are ineffective due to resistance.
Side Effects
Common side effects of Posizolid include:
Serious side effects can include myelosuppression, peripheral neuropathy, and lactic acidosis.
Resistance
Resistance to Posizolid is relatively rare but can occur through mutations in the 23S rRNA of the bacterial ribosome or through the acquisition of the cfr gene, which confers resistance to multiple antibiotic classes.
